Legal
FTC Says Settlement Talks to Resolve Blocked Amgen-Horizon Deal Have Ended
- Agency sued in May in first pharma deal challenge in a decade
- US judge to hear case in September, rule by late October
This article is for subscribers only.
The Federal Trade Commission said that there are no ongoing talks with Amgen Inc. to resolve a legal challenge to it $27.8 billion takeover of Horizon Therapeutics Plc after the agency rejected a settlement overture made earlier this year.
During a hearing Wednesday in the FTC’s in-house court, agency lawyer Nathan Brenner said the FTC engaged in settlement discussions earlier in the case and remains “open to hearing proposals.”